Charles Schwab Investment Management Inc. Sells 111,684 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Charles Schwab Investment Management Inc. reduced its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 17.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 511,720 shares of the company's stock after selling 111,684 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.72% of Nurix Therapeutics worth $11,498,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in NRIX. SG Americas Securities LLC grew its position in shares of Nurix Therapeutics by 365.0% in the second quarter. SG Americas Securities LLC now owns 103,199 shares of the company's stock valued at $2,154,000 after purchasing an additional 81,005 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Nurix Therapeutics by 80.7% during the second quarter. Renaissance Technologies LLC now owns 324,000 shares of the company's stock worth $6,762,000 after buying an additional 144,700 shares during the last quarter. TD Asset Management Inc acquired a new position in shares of Nurix Therapeutics during the second quarter worth approximately $593,000. Candriam S.C.A. boosted its position in shares of Nurix Therapeutics by 30.5% in the second quarter. Candriam S.C.A. now owns 1,164,246 shares of the company's stock valued at $24,297,000 after acquiring an additional 272,136 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Nurix Therapeutics by 31.4% in the second quarter. Bank of New York Mellon Corp now owns 209,136 shares of the company's stock worth $4,365,000 after acquiring an additional 49,918 shares during the last quarter.

Nurix Therapeutics Trading Down 3.3 %

Shares of Nurix Therapeutics stock traded down $0.71 during mid-day trading on Monday, reaching $20.66. 962,379 shares of the stock were exchanged, compared to its average volume of 901,363. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -7.04 and a beta of 2.11. Nurix Therapeutics, Inc. has a fifty-two week low of $7.65 and a fifty-two week high of $29.56. The firm has a 50-day simple moving average of $23.75 and a 200 day simple moving average of $22.02.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.67). The company had revenue of $12.59 million during the quarter, compared to analysts' expectations of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. On average, research analysts predict that Nurix Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on NRIX shares. UBS Group initiated coverage on shares of Nurix Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $35.00 price target for the company. Royal Bank of Canada reduced their target price on shares of Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating for the company in a research note on Monday, October 14th. Needham & Company LLC restated a "buy" rating and set a $29.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, November 6th. HC Wainwright lifted their price objective on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Finally, Jefferies Financial Group assumed coverage on Nurix Therapeutics in a research report on Friday, October 11th. They set a "buy" rating and a $41.00 price objective on the stock. One analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $29.75.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Christine Ring sold 5,760 shares of the company's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $22.23, for a total transaction of $128,044.80. Following the transaction, the insider now owns 24,592 shares of the company's stock, valued at approximately $546,680.16. This represents a 18.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 2,368 shares of the company's stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $57,542.40. Following the transaction, the chief financial officer now directly owns 37,270 shares in the company, valued at $905,661. This trade represents a 5.97 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,401 shares of company stock worth $437,453. 7.20% of the stock is currently owned by insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.